Chinese CDMOs Excluded from Supply Chain by Biosecurity Act
An Opportunity to Boost Global Market Share

Union Risks Emerge for Korean Firms Like Samsung Biologics
China Supports Industry with Multi-Trillion Yuan National Funds and Tax Benefits

The domestic contract development and manufacturing organization (CDMO) industry has encountered an opportunity to widen its technological and order gap with Chinese competitors following the enactment of the U.S. Biosecurity Act. However, internal risks are intensifying concerns within the industry. In particular, the spread of excessive demands for profit-sharing and labor union conflicts across the industrial sector is raising significant worries.


According to the industry on June 22, the Biosecurity Act, which came into effect at the end of last year, restricts U.S. administrative agencies from procuring or contracting equipment and services from "of-concern bio companies" deemed to pose a threat to national security. The U.S. Office of Management and Budget (OMB) is required to publicize the list of such companies within one year of the law's enactment. As major Chinese CDMO companies such as WuXi Biologics and China Leading Biotech are expected to be included on this list, there is growing anticipation that domestic CDMO companies such as Samsung Biologics will be able to structurally expand their global market share and secure market leadership, thereby clearly widening the gap with their Chinese competitors.


However, since the enactment of the U.S. Biosecurity Act, concerns have grown that the rise of labor union risks in the Korean industry may cause domestic companies to miss this opportunity to pull ahead of Chinese CDMOs. A representative example is Samsung Biologics, which is experiencing conflicts with management over demands for a 14% wage increase and prior union consent for new hires. After negotiations broke down, early last month, more than 2,800 union members at Samsung Biologics initiated a full-scale strike, and they continue to engage in a form of "legal struggle" by refusing extended and holiday work. Management estimates that the strike has already resulted in damages amounting to several hundred billion won. There are also concerns that the so-called "equal profit-sharing" movements and labor disputes at major conglomerates, which are spreading like a trend, could prompt similar disputes at other companies in the industry.


In the CDMO business, securing preemptive capacity ahead of market demand is essential. However, if management's attention is diverted to internal conflict due to labor disputes, they may miss the optimal timing for key investment decisions such as launching new plants. If the rigidity in workforce management caused by strikes continues, there is also a risk that the operational start of newly constructed plants will be delayed. Most importantly, if the risk of production stoppages causes global pharmaceutical companies to hesitate on long-term contracts, the rationale for expansion will be undermined.


U.S. Biosecurity Act Offers Chance to Widen Gap With China, but Korean CDMOs Hindered by Union Risks View original image

In contrast, Chinese CDMO companies are pursuing aggressive capacity expansion based on favorable domestic policies. The Chinese government, through the enactment of the Enterprise Income Tax Law of the People's Republic of China, applies a reduced tax rate of 15%—lower than the standard corporate tax rate of 25%—to new drug development and CDMO companies. Additionally, government-led funds totaling more than 31.493 billion yuan (approximately 6.0151 trillion won) are being invested exclusively in the life sciences sector to foster domestic new drug development companies and build China's CDMO industry infrastructure. According to the Korea Institute of S&T Evaluation and Planning (KISTEP), China has raised the competitiveness of its overall bio ecosystem by attracting 58,000 talents, including 7,000 top-tier scientists, to return home through the "Thousand Talents Program" (Bai Ren Ji Hua).


With full government support, Chinese CDMO companies are enhancing their global competitiveness. WuXi Biologics is aiming to expand its total production capacity to more than 580,000 liters within this year, leveraging its sites in China (about 260,000 liters), Singapore (120,000 liters), Ireland (54,000 liters), North America (about 42,000 liters), and Germany (about 24,000 liters). China Leading Biotech is also implementing aggressive expansion, having secured a production capacity of around 700,000 liters. According to Bioplan Associates and others, China Leading Biotech’s plants in Shenzhen and Shanghai are ranked as the world's second and sixth largest single production facilities, respectively, demonstrating their rapid expansion.



Jung Yoon-taek, Director of the Pharmaceutical Industry Strategy Research Institute, stated, "China is going beyond simple contract manufacturing, designating biotechnology as a national strategic industry and leading advanced bio license-outs based on massive cluster subsidies, thereby threatening global 'bio supremacy.' Compared to China, where national leadership and support are accelerating rapid growth, internal labor-management conflicts at Korean companies can only negatively impact their ability to secure global leadership."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing